TOP > 外国特許検索 > ARTIFICIAL RED BLOOD CELL HAVING ABILITY TO INHIBIT TRANSFORMATION OF HEMOGLOBIN INTO METHEMOGLOBIN

ARTIFICIAL RED BLOOD CELL HAVING ABILITY TO INHIBIT TRANSFORMATION OF HEMOGLOBIN INTO METHEMOGLOBIN NEW 新技術説明会

外国特許コード F170009262
整理番号 (S2016-0227-N0)
掲載日 2017年10月24日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2017JP008187
国際公開番号 WO 2017150637
国際出願日 平成29年3月1日(2017.3.1)
国際公開日 平成29年9月8日(2017.9.8)
優先権データ
  • 特願2016-040494 (2016.3.2) JP
発明の名称 (英語) ARTIFICIAL RED BLOOD CELL HAVING ABILITY TO INHIBIT TRANSFORMATION OF HEMOGLOBIN INTO METHEMOGLOBIN NEW 新技術説明会
発明の概要(英語) The present invention inhibits, in an artificial red blood cell containing purified and enriched hemoglobin that substantially has no enzymatic activity to reduce methemoglobin, transformation of the hemoglobin into methemoglobin. Provided is an artificial red blood cell which comprises: an aqueous solution that contains NADH and/or NADPH and hemoglobin; and a capsule that includes the aqueous solution, wherein the aqueous solution and the capsule substantially have no enzymatic activity to reduce methemoglobin.
特許請求の範囲(英語) [claim1]
1. NADH and/or it consists of with the capsule which contains the aqueous solution and the said aqueous solution which include NADPH and the hemoglobin, as for the aforementioned aqueous solution or the capsule substantially there is no enzyme activity which restores the methemoglobin, the artificial red corpuscle.
[claim2]
2. 50% meto conversion hour of the hemoglobin is 72 hours or more, in claim 1 the artificial red corpuscle of statement.
[claim3]
3. Hemoglobin density in the aqueous solution which is contained in the aforementioned capsule is 10g/dL-45g/dL (1.6mM-7.0mM), NADH in the said aqueous solution and/or the molar concentration of NADPH is 0.5-10 two times the molar concentration of the hemoglobin, in claim 1 or 2 the artificial red corpuscle of statement.
[claim4]
4. Pyridoxal 5 of molar concentration of 0.5-3 two times the molar concentration of the hemoglobin in the 2nd aqueous solution ' - phosphate is included in the 2nd aqueous solution, claim either 1 or 3 in 1 sections the artificial red corpuscle of statement.
[claim5]
5. The aforementioned capsule at least is one which is selected from the group which consists of liposome, porimasomu and the high-molecular thin film, claim either 1 or 4 in 1 sections the artificial red corpuscle of statement.
[claim6]
6. As for the aforementioned liposome, 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC),
cholesterol,
1,5-O-dihexadecyl-N-succinyl-L-glutamate (DHSG) and 1,2-distearoyl-sn-glycero-3-phosphatidylethanolamine-N-PEG [50000] (DSPE-PEG [5000])
It consists of, in claim 5 the artificial red corpuscle of statement.
[claim7]
7. Claim either 1 or 6 the formulation for transfusion substitution which includes the artificial red corpuscle of statement in 1 sections.
[claim8]
8. Claim either 1 or 6 it includes the artificial red corpuscle of statement in 1 sections when it is dispersed in the aqueous solution, furthermore, in the said aqueous solution, it includes at the density which is allowed the chemical compound of 1 where it is selected from the group which consists of electrolyte, sugar, amino acid, colloid, NADH and NADPH types at least physiologically, in claim 7 the formulation for transfusion substitution of statement.
[claim9]
9. NADH and/or the capsule which contains the aqueous solution of NADPH is included, NO and H [2] O [2] and O [2] (- at least the elimination medicine of one which is selected from the group which consists of) substance.
[claim10]
10. Being production method of the artificial red corpuscle,
(A) From the 1st aqueous solution which includes the hemoglobin the methemoglobin the step which removes the enzyme activity which is restored substantially and,
(B) Melting NADH and/or NADPH in the 1st aqueous solution, hemoglobin and NADH which is not the enzyme activity which substantially restores the methemoglobin and/or the step which prepares the 2nd aqueous solution which includes NADPH and,
(C) Containing the 2nd aqueous solution in the capsule, it includes with the 2nd aqueous solution and the step which obtains the artificial red corpuscle which the capsule consists of, production method of the artificial red corpuscle.
[claim11]
11. The aforementioned step (a), the 1st aqueous solution at the 60-65.deg.C the fact that 1-12 time it heats is included, in claim 10 production method of the artificial red corpuscle of statement.
[claim12]
12. Hemoglobin density in the 2nd aqueous solution is 10g/dL-45g/dL (1.6mM-7.0mM), NADH in the 2nd aqueous solution and/or the molar concentration of NADPH is 0.5-10 two times the molar concentration of the hemoglobin, in claim 10 or 11 production method of the artificial red corpuscle of statement.
[claim13]
13. The aforementioned step (b) in, pyridoxal 5 of molar concentration of 0.5-3 two times the molar concentration of the hemoglobin in the 2nd aqueous solution ' - phosphate is included in the 2nd aqueous solution, claim either 10 or 12 in 1 sections production method of the artificial red corpuscle of statement.
[claim14]
14. The aforementioned step (b), pyridoxal 5 ' - phosphate the 1st aqueous solution or the fact that it melts in 2nd aqueous solution is included, in claim 13 production method of the artificial red corpuscle of statement.
[claim15]
15. The aforementioned capsule at least is one which is selected from the group which consists of liposome, porimasomu and the high-molecular thin film, claim either 10 or 14 in 1 sections production method of the artificial red corpuscle of statement.
[claim16]
16. As for the aforementioned liposome, 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC),
cholesterol,
1,5-O-dihexadecyl-N-succinyl-L-glutamate (DHSG) and 1,2-distearoyl-sn-glycero-3-phosphatidylethanolamine-N-PEG [5000] (DSPE-PEG [5000])
It consists of, in claim 15 production method of the artificial red corpuscle of statement.
[claim17]
17. The medicine composition for the methemoglobinemia prevention which claim either 1 or 6 includes the artificial red corpuscle of statement in 1 sections, in the remedy of the blood poisoning, the remedy and NO inhalation medical therapy of large quantity intake of the nitrous acid salt.
[claim18]
18. In claim the formulation for transfusion substitution of statement is included 7 or 8, in claim 17 the medicine composition of statement.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NARA MEDICAL UNIVERSITY
  • 発明者(英語)
  • SAKAI HIROMI
  • YAMADA MAGOHEI
国際特許分類(IPC)
指定国 (WO2017150637)
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG

PAGE TOP

close
close
close
close
close
close